Factors associated with the overall survival of elderly patients with hepatocellular carcinoma
Related Experiment Video
Updated: May 22, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Hideki Fujii1, Yoshito Itoh, Naoki Ohnishi
1Department of Internal Medicine, Aiseikai Yamashina Hospital, Kyoto 602-8566, Japan.
Insights
Overall survival in elderly hepatocellular carcinoma (HCC) patients depends on liver damage and cancer stage, not age itself. However, patients aged 80 and above with a good hepatic reserve may have reduced survival.
Area of Science:
- Hepatology
- Geriatric Oncology
- Cancer Epidemiology
Background:
- Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in aging populations.
- Understanding survival factors in elderly HCC patients is crucial for optimizing treatment strategies.
Purpose of the Study:
- To determine the key factors influencing overall survival in elderly patients diagnosed with hepatocellular carcinoma (HCC).
Main Methods:
- A cohort of 286 HCC patients (age 46-100) were analyzed, stratified into elderly (≥75 years) and non-elderly groups.
- Clinical characteristics and survival rates were compared using univariate and multivariate analyses.
- Kaplan-Meier method and log-rank tests assessed survival based on age, modified Japan Integrated Stage (mJIS) score, and hepatic reserve capacity.
Main Results:
- Elderly patients showed a higher prevalence of female sex, absence of viral hepatitis, and comorbidities.
- Overall survival rates at 3 and 5 years were comparable between elderly and non-elderly groups.
- Multivariate analysis identified liver damage and tumor stage as significant survival predictors, independent of age, except for individuals ≥80 years with mJIS score ≤2.
Conclusions:
- Hepatocellular carcinoma patient survival is primarily linked to the extent of liver damage and disease stage.
- Age is not an independent predictor of survival in HCC, with a notable exception for very elderly patients (≥80 years) with good hepatic reserve.
- Treatment and prognostic considerations for elderly HCC patients should focus on disease-specific factors rather than chronological age alone.
Aim:
To identify the factors associated with overall survival of elderly patients with hepatocellular carcinoma (HCC).
Methods:
A total of 286 patients with HCC (male/female: 178/108, age: 46-100 years), who were diagnosed and treated by appropriate therapeutic procedures between January 2000 and December 2010, were enrolled in this study. Patients were stratified into two groups on the basis of age: Elderly (≥ 75 years old) and non-elderly (< 75 years old). Baseline clinical characteristics as well as cumulative survival rates were then compared between the two groups. Univariate and multivariate analyses were used to identify the factors associated with prolonged overall survival of patients in each group. Cumulative survival rates in the two groups were calculated separately for each modified Japan Integrated Stage score (mJIS score) category by the Kaplan-Meier method. In addition, we compared the cumulative survival rates of elderly and non-elderly patients with good hepatic reserve capacity (≤ 2 points as per mJIS).
Results:
In the elderly group, the proportion of female patients, patients with absence of hepatitis B or hepatitis C viral infection, and patients with coexisting extrahepatic comorbid illness was higher (56.8% vs 31.1%, P < 0.001; 27.0% vs 16.0%, P = 0.038; 33.8% vs 22.2%, P = 0.047; respectively) than that in the non-elderly group. In the non-elderly group, the proportion of hepatitis B virus (HBV)-infected patients was higher than that in the elderly group (9.4% vs 0%, P = 0.006). The cumulative survival rates in the elderly group were 53.7% at 3 years and 32.9% at 5 years, which were equivalent to those in the non-elderly group (55.9% and 39.4%, respectively), as shown by a log-rank test (P = 0.601). In multivariate analysis, prolonged survival was significantly associated with the extent of liver damage and stage (P < 0.001 and P < 0.001, respectively), but was not associated with patient age. However, on individual evaluation of factors in both groups, stage was significantly (P < 0.001) associated with prolonged survival. Regarding mJIS scores of ≤ 2, the rate of female patients with this score was higher in the elderly group when compared to that in the non-elderly group (P = 0.012) and patients ≥ 80 years of age tended to demonstrate shortened survival.
Conclusion:
Survival of elderly HCC patients was associated with liver damage and stage, but not age, except for patients ≥ 80 years with mJIS score ≤ 2.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cancer Survival Analysis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Bioavailability: Influencing Factors
Hepatic Drug Excretion: Influencing Factors
Drug Dosing: Geriatric Patients
